ArticleFrontiers in immunology2025
Immunophenotyping of septic shock patients with endotheliopathy: focus on monocyte subtypes and Immune regulatory molecules.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Septic shock is characterized by dysregulation of the host response to infection Q5 which results in life-threatening organ dysfunction that can be partly attributed to immune alterations and endothelial dysfunction (endotheliopathy). This lethal condition is dynamic, complex, and heterogeneous. Aim: Thus, an exploratory broad phenotypic and functional analysis of circulating immune cells and mediators were carried out to better understand the role of the immune system in a subgroup of septic shock patients with endotheliopathy defined by increased levels of soluble thrombomodulin (sTM). In this regard, especially the immune status of monocyte subtypes (classical, intermediate, and nonclassical) was investigated for surface thrombomodulin (TM), MHC class II molecules (HLADR, -DQ, and -DP) and immunomodulatory surface receptors (TREM-1, CD137, VISTA, HVEM and BTLA). Result and conclusion: Our comprehensive immunophenotypic analysis on a septic shock cohort with endotheliopathy identified distinct immune perturbation patterns that potentially can lead to novel treatment avenues in the management of this life-threatening condition.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.